Regeneron abandons respiratory syncytial virus therapy after late-stage failure
pharmafile | August 15, 2017 | News story | Manufacturing and Production, Research and Development | RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus
Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the company has decided to scrap its further development, stripping what was once a high-potential asset from its portfolio.
REGN2222, as the drug is known, failed in a recent Phase 3 trial to meet its primary endpoint of preventing medically attended RSV infections in infants. However, the company did make it known that the therapy did show efficacy in a subgroup of patients
In the trial, 1,149 infants aged six months or younger were given 30mg/kg suptavumab as a single dose or a twin dose administered eight weeks apart, or placebo. Patients were monitored for 150 days to ascertain whether they required medical attention at any point, defined as hospitalisation or seeking medical care as a result of their RSV infection.
“We are disappointed in these results, as we had hoped suptavumab might offer a new option for the thousands of infants impacted by serious RSV infections every year,” said Regeneron CSO George Yancopoulos in a statement. “Regeneron has a robust pipeline across many serious diseases, and we look forward to important data readouts from other programs in the coming weeks and months,”
The news is unlikely to cause any great impact to Regeneron or the wider public; the US firm has seen a string of successes in recent times that can comfortably offset this unfortunate set of events, while, according to the WHO, there are over 20 candidates from 12 different companies already in the RSV vaccine pipeline, meaning there is still promise of an effective preventative measure being made available to patients down the line.
Matt Fellows
Related Content
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with …
